Multiple Sclerosis Clinical Trials in Washington

18 recruiting studies across 1 city

Browse by City

All Trials in Washington

Phase

Trial	Phase	Sponsor	Dist.
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	<1 mi
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis	N/A	Accelerated Cure Project for Multiple Sclerosis	<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)	Phase 2	Hoffmann-La Roche	<1 mi
Increasing Physical Activity for Adults With Multiple Sclerosis (MS)	N/A	University of Washington	<1 mi
Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue	N/A	University of Washington	<1 mi
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis	Phase 1	University of Washington	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis	Phase 1	AstraZeneca	<1 mi
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study	N/A	SetPoint Medical Corporation	<1 mi
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases	Phase 1	Kite, A Gilead Company	<1 mi
Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice	N/A	University of Washington	<1 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity	Phase 2	Celgene	8 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	8 mi
Complementary and Alternative Care in Multiple Sclerosis	—	Bastyr University	11 mi
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy	Phase 4	Genentech, Inc.	25 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.